Long Non-Coding RNA and Acute Leukemia

Cruz-Miranda, Gabriela Marisol; Hidalgo-Miranda, Alfredo; Bárcenas-López, Diego Alberto; Núñez-Enríquez, Juan Carlos; Ramírez‐Bello, Julián; Mejı́a-Aranguré, Juan Manuel; Jiménez-Morales, Silvia

doi:10.3390/ijms20030735

Cited by 48 publications

(32 citation statements)

References 99 publications

(126 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They required a high grade of expertise and different laboratory standards, they were time consuming and expensive, and no single test could accurately discriminate ALL from AML alone. MiRNA ( 38 , 39 ) and long noncoding RNA (lncRNA) ( 40 , 41 ) have also been shown in recent years to be useful in the diagnosis of AL. However, the role of circRNAs in AL remains largely unknown.…”

Section: Discussionmentioning

confidence: 99%

Hsa_circ_0012152 and Hsa_circ_0001857 Accurately Discriminate Acute Lymphoblastic Leukemia From Acute Myeloid Leukemia

Guo

Chen

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

Acute leukemia (AL) is a group of highly heterogeneous hematological malignancies. Circular RNAs (circRNAs) are covalently closed circRNA molecules implicated in the development of many diseases. However, the role of circRNAs in AL remains largely unknown. Therefore, this study aimed to identify new classification diagnostic biomarkers for subgroups of AL. The circRNA expression signatures discriminating acute lymphoblastic leukemia (ALL) from acute myeloid leukemia (AML) were identified by microarray, followed by reverse transcription quantitative polymerase chain reaction (RT-qPCR) validation. Receiver operating characteristic curve analysis was used to evaluate the diagnostic efficiencies of hsa_circ_0001857 and hsa_circ_0012152, and hsa_circ_0012152 was selected for Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analysis. The results showed that the circRNA expression profiles, hsa_circ_0001857, and hsa_circ_0012152 could clearly discriminate ALL from AML. The target genes of hsa_circ_0012152 might be involved in biological processes, such as myeloid cell differentiation, covalent chromatin modification, histone modification, and rat sarcoma (Ras) protein signal transduction, and participate in pathways such as mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3′-kinase (PI3K)-Akt signaling pathway. Hsa_circ_0012152 might be involved in the initiation and development of AML through miR-491-5p/epidermal growth factor receptor (EGFR)/MAPK1 or miR-512-3p/EGFR/MAPK1 axis. Our results showed that circRNA expression profiles and specifically expressed circRNAs were promising classification biomarkers to designate AL into ALL or AML.

show abstract

Section: Discussionmentioning

confidence: 99%

Hsa_circ_0012152 and Hsa_circ_0001857 Accurately Discriminate Acute Lymphoblastic Leukemia From Acute Myeloid Leukemia

Guo

Chen

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…This has opened space for disclosure and portrayal of non-coding RNAs as biomarkers in leukemia and prompted several investigations in this field over the last 10 years. The full picture of these unusually communicating non-coding RNAs in leukemia is slowly developing [9][10][11][12][13][14][15][16][17]. The vital role and underlying molecular mechanisms of non-coding RNAs and their therapeutic potential in leukemia are outlined in Table 1.…”

Section: Non-coding Rna Network and Leukemiamentioning

confidence: 99%

“…Numerous lncRNAs are deregulated in different sorts of malignant growths, including head and neck cancer [92]. Unmistakable expression profiles of lncRNA have been distinguished in leukemia [9,33,35,45,[47][48][49][93][94][95][96][97][98][99]. Some of these have been demonstrated to have wellunderstood jobs in the development and progression of leukemia, suggesting the vital use of lncRNAs as novel biomarkers and potential targets for the treatment of leukemia.…”

Section: Long Non-coding Rnasmentioning

confidence: 99%

Role of non-coding RNA networks in leukemia progression, metastasis and drug resistance

et al. 2020

View full text Add to dashboard Cite

Early-stage detection of leukemia is a critical determinant for successful treatment of the disease and can increase the survival rate of leukemia patients. The factors limiting the current screening approaches to leukemia include low sensitivity and specificity, high costs, and a low participation rate. An approach based on novel and innovative biomarkers with high accuracy from peripheral blood offers a comfortable and appealing alternative to patients, potentially leading to a higher participation rate. Recently, non-coding RNAs due to their involvement in vital oncogenic processes such as differentiation, proliferation, migration, angiogenesis and apoptosis have attracted much attention as potential diagnostic and prognostic biomarkers in leukemia. Emerging lines of evidence have shown that the mutational spectrum and dysregulated expression of non-coding RNA genes are closely associated with the development and progression of various cancers, including leukemia. In this review, we highlight the expression and functional roles of different types of non-coding RNAs in leukemia and discuss their potential clinical applications as diagnostic or prognostic biomarkers and therapeutic targets.

show abstract

“…Long non-coding RNAs can directly or indirectly regulate different pathways in cancer ( 27 ), and their relevance for hematological malignancies in particular has been established at a rapid pace ( 28 – 37 ). Well known transcription factors and or proto-oncoproteins such as c- Myelocytomatosis viral oncogene homolog (MYC), Notch1 , beta-catenin , or RAS regulate lncRNAs or are being regulated by lncRNAs in different hematological disorders ( 38 – 43 ), [reviewed in ( 29 , 30 , 44 )]. One of the most frequently activated proto-oncogenes in human cancers is the c-MYC gene ( MYC henceforth).…”

Section: Introductionmentioning

confidence: 99%

Crosstalk Between MYC and lncRNAs in Hematological Malignancies

Arman

Möröy

2020

Front. Oncol.

View full text Add to dashboard Cite

The human genome project revealed the existence of many thousands of long non-coding RNAs (lncRNAs). These transcripts that are over 200 nucleotides long were soon recognized for their importance in regulating gene expression. However, their poor conservation among species and their still controversial annotation has limited their study to some extent. Moreover, a generally lower expression of lncRNAs as compared to protein coding genes and their enigmatic biochemical mechanisms have impeded progress in the understanding of their biological roles. It is, however, known that lncRNAs engage in various kinds of interactions and can form complexes with other RNAs, with genomic DNA or proteins rendering their functional regulatory network quite complex. It has emerged from recent studies that lncRNAs exert important roles in gene expression that affect many cellular processes underlying development, cellular differentiation, but also the pathogenesis of blood cancers like leukemia and lymphoma. A number of lncRNAs have been found to be regulated by several well-known transcription factors including Myelocytomatosis viral oncogene homolog ( MYC ). The c-MYC gene is known to be one of the most frequently deregulated oncogenes and a driver for many human cancers. The c- MYC gene is very frequently activated by chromosomal translocations in hematopoietic cancers most prominently in B- or T-cell lymphoma or leukemia and much is already known about its role as a DNA binding transcriptional regulator. Although the understanding of MYC’s regulatory role controlling lncRNA expression and how MYC itself is controlled by lncRNA in blood cancers is still at the beginning, an intriguing picture emerges indicating that c-MYC may execute part of its oncogenic function through lncRNAs. Several studies have identified lncRNAs regulating c- MYC expression and c-MYC regulated lncRNAs in different blood cancers and have unveiled new mechanisms how these RNA molecules act. In this review, we give an overview of lncRNAs that have been recognized as critical in the context of activated c-MYC in leukemia and lymphoma, describe their mechanism of action and their effect on transcriptional reprogramming in cancer cells. Finally, we discuss possible ways how an interference with their molecular function could be exploited for new cancer therapies.

show abstract

Long Non-Coding RNA and Acute Leukemia

Cited by 48 publications

References 99 publications

Hsa_circ_0012152 and Hsa_circ_0001857 Accurately Discriminate Acute Lymphoblastic Leukemia From Acute Myeloid Leukemia

Hsa_circ_0012152 and Hsa_circ_0001857 Accurately Discriminate Acute Lymphoblastic Leukemia From Acute Myeloid Leukemia

Role of non-coding RNA networks in leukemia progression, metastasis and drug resistance

Crosstalk Between MYC and lncRNAs in Hematological Malignancies

Contact Info

Product

Resources

About